Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease.

European Journal of Medicinal Chemistry
Sergio Rodriguez-ArevaloCarmen Escolano

Abstract

Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in silico of a family of benzofuranyl-2-imidazoles that exhibit affinity against human brain I2-IR and most of them have been predicted to be brain permeable. Acute treatment in mice with 2-(2-benzofuranyl)-2-imidazole, known as LSL60101 (garsevil), showed non-warning properties in the ADMET studies and an optimal pharmacokinetic profile. Moreover, LSL60101 induced hypothermia in mice while decreased pro-apoptotic FADD protein in the hippocampus. In vivo studies in the familial Alzheimer's disease 5xFAD murine model with the representative compound, revealed significant decreases in the protein expression levels of antioxidant enzymes superoxide dismutase and glutathione peroxidase in hippocampus. Overall, LSL60101 plays a neuroprotective role by reducing apoptosis and modulating oxidative stress.

References

Jan 1, 1992·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·K MaieseD J Reis
Jul 4, 1995·European Journal of Pharmacology·R AlemanyJ A García-Sevilla
Feb 20, 1997·The New England Journal of Medicine·D W MarionS T DeKosky
Feb 1, 1997·Clinical and Experimental Pharmacology & Physiology·J A Craven, E L Conway
Jul 9, 1998·Neuroscience Letters·J A García-SevillaJ Guimón
Jul 23, 1999·Annals of the New York Academy of Sciences·S RegunathanD J Reis
Apr 20, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·L F CalladoJ J Meana
Jun 30, 2004·Medicinal Research Reviews·Christophe Dardonville, Isabel Rozas
Nov 14, 2008·Stress : the International Journal on the Biology of Stress·Karen L SmithDavid P Finn
Apr 17, 2010·Neuropharmacology·David J BondaMark A Smith
Mar 5, 2011·European Journal of Pharmacology·Jun-Xu Li, Yanan Zhang
Feb 14, 2012·British Journal of Pharmacology·David A ThornJun-Xu Li
Dec 27, 2012·The World Allergy Organization Journal·Esra BirbenOmer Kalayci
Mar 29, 2014·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·J A Lowry, J T Brown
Dec 29, 2016·ACS Chemical Neuroscience·Sònia AbásCarmen Escolano
Mar 23, 2017·Pharmacology & Therapeutics·Jun-Xu Li
Mar 11, 2018·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Robin J TyackeDavid J Nutt
Aug 26, 2018·Biochemical and Biophysical Research Communications·Dong-Hee ChoiJongmin Lee
Nov 22, 2018·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Christian Griñán-FerréMercè Pallàs
Dec 11, 2019·Pharmacological Reviews·Pascal BousquetJun-Xu Li
Mar 10, 2020·Journal of Medicinal Chemistry·Sònia AbásCarmen Escolano
Jan 9, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology·Elena Hernández-Hernández, M Julia García-Fuster

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis